- Home
- FRME vs AMPH Comparison
FRME vs AMPH Comparison
Compare FRME & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRME
- AMPH
- Stock Information
- Founded
- FRME 1893
- AMPH 1996
- Country
- FRME United States
- AMPH United States
- Employees
- FRME N/A
- AMPH N/A
- Industry
- FRME Major Banks
- AMPH Biotechnology: Pharmaceutical Preparations
- Sector
- FRME Finance
- AMPH Health Care
- Exchange
- FRME Nasdaq
- AMPH Nasdaq
- Market Cap
- FRME 2.1B
- AMPH 2.5B
- IPO Year
- FRME N/A
- AMPH 2014
- Fundamental
- Price
- FRME $37.96
- AMPH $51.45
- Analyst Decision
- FRME Buy
- AMPH Buy
- Analyst Count
- FRME 5
- AMPH 4
- Target Price
- FRME $43.90
- AMPH $63.00
- AVG Volume (30 Days)
- FRME 248.8K
- AMPH 268.7K
- Earning Date
- FRME 10-24-2024
- AMPH 11-06-2024
- Dividend Yield
- FRME 3.78%
- AMPH N/A
- EPS Growth
- FRME N/A
- AMPH 62.07
- EPS
- FRME 3.01
- AMPH 3.15
- Revenue
- FRME $593,089,000.00
- AMPH $712,891,000.00
- Revenue This Year
- FRME N/A
- AMPH $18.04
- Revenue Next Year
- FRME $3.02
- AMPH $4.41
- P/E Ratio
- FRME $12.35
- AMPH $16.26
- Revenue Growth
- FRME N/A
- AMPH 31.80
- 52 Week Low
- FRME $26.85
- AMPH $36.56
- 52 Week High
- FRME $42.45
- AMPH $65.92
- Technical
- Relative Strength Index (RSI)
- FRME 53.37
- AMPH 59.40
- Support Level
- FRME $35.13
- AMPH $49.38
- Resistance Level
- FRME $37.35
- AMPH $51.84
- Average True Range (ATR)
- FRME 1.17
- AMPH 1.25
- MACD
- FRME -0.06
- AMPH 0.10
- Stochastic Oscillator
- FRME 54.14
- AMPH 78.90
About FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.
About AMPH Amphastar Pharmaceuticals Inc.
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.